ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)

NCT03786003 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Not applicable

Started

2022-02-09

Last updated

2023-07-21

Condition(s) studied

Carcinoma, Non-Small-Cell Lung

Investigational drug(s) / intervention(s)

VATSThoracotomy

VATS: Standard video assisted thoracic surgery, no use of rib-spreader.

Thoracotomy: Standard thoracotomy

Study summary

This study is one of Eastern Cooperative Thoracic Oncology Projects (ECTOP-1007). The goal of this study is to determine video-assisted thoracoscopic surgery is non-inferior to thoracotomy in terms of disease-free survival for solid clinical stage T1N0M0 NSCLC.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Accepted

Inclusion Criteria: * Clinical stage T1N0M0 and surgical resectable. * Solid appearance on computed tomography scan. * Age 18 to 75 year. * Signed the informed consent form. Exclusion Criteria: * Not NSCLC in pathological analysis. * Not lobectomy or sublobar resection. * History of other malignant tumors within 5 years. * History of thoracic surgery or unsuitable for VATS. * Previous radiation or chemotherapy.

Primary outcome measure(s)

Disease-free survival — 3 years after the surgery
Disease-free survival means the period after surgery when no disease can be detected.

Trial sites (1)

Facility	City	Region	Status
Fudan University Shanghai Cancer Center	Shanghai	China	Recruiting

More Fudan University trials in China

Real-World Study of Young Patients With Solid Tumors in China Recruiting

Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer Starting soon

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases Active, not recruiting

Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors Active, not recruiting

Zhongshan Ketogenic Diet Study 1 Recruiting

Other trials for the same condition

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors Recruiting

SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer Active, not recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) Recruiting

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03786003 on ClinicalTrials.gov ↗ ← All trials in China